Arcturus Therapeutics Holdings Inc.ARCTEarnings & Financial Report
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
Revenue
$38.0M
Gross Profit
N/A
Operating Profit
$-30.4M
Net Profit
$-26.8M
Gross Margin
N/A
Operating Margin
-80.0%
Net Margin
-70.5%
YoY Growth
-52.7%
EPS
$-1.00
Arcturus Therapeutics Holdings Inc. Q1 FY2024 Financial Summary
Arcturus Therapeutics Holdings Inc. reported revenue of $38.0M (down 52.7% YoY) for Q1 FY2024, with a net profit of $-26.8M (down 152.8% YoY) (-70.5% margin).
Key Financial Metrics
| Total Revenue | $38.0M |
|---|---|
| Net Profit | $-26.8M |
| Gross Margin | N/A |
| Operating Margin | -80.0% |
| Report Period | Q1 FY2024 |
Revenue Breakdown
Arcturus Therapeutics Holdings Inc. Q1 FY2024 revenue of $38.0M breaks down across 2 segments, led by Collaboration Revenue at $32.6M (85.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Collaboration Revenue | $32.6M | 85.8% |
| Biomedical Advanced Research And Development Authority | $5.5M | 14.5% |
Arcturus Therapeutics Holdings Inc. Revenue by Segment — Quarterly Trend
Arcturus Therapeutics Holdings Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Collaboration Revenue and Biomedical Advanced Research And Development Authority) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Collaboration Revenue | — | — | $24.5M | $25.5M |
Arcturus Therapeutics Holdings Inc. Annual Revenue by Year
Arcturus Therapeutics Holdings Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $82.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $82.0M |
| 2024 | $152.3M |
| 2023 | $166.8M |
| 2022 | $206.0M |
Arcturus Therapeutics Holdings Inc. Quarterly Revenue & Net Profit History
Arcturus Therapeutics Holdings Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $7.2M | -68.4% | N/A | N/A |
| Q3 FY2025 | $17.2M | -58.8% | $-13.4M | -78.4% |
| Q2 FY2025 | $28.3M | -43.2% | $-9.2M | -32.4% |
| Q1 FY2025 | $29.4M | -22.7% | $-14.1M | -47.9% |
| Q4 FY2024 | $22.8M | -26.2% | $-30.0M | -131.8% |
| Q3 FY2024 | $41.7M | -7.7% | $-6.9M | -16.6% |
| Q2 FY2024 | $49.9M | +374.0% | $-17.2M | -34.5% |
| Q1 FY2024 | $38.0M | -52.7% | $-26.8M | -70.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38.0M | $49.9M | $41.7M | $22.8M | $29.4M | $28.3M | $17.2M | $7.2M |
| YoY Growth | -52.7% | 374.0% | -7.7% | -26.2% | -22.7% | -43.2% | -58.8% | -68.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $418.8M | $388.6M | $370.7M | $344.1M | $331.8M | $309.3M | $282.3M | $271.1M |
| Liabilities | $154.9M | $130.0M | $108.8M | $103.1M | $98.0M | $78.2M | $57.8M | $57.2M |
| Equity | $264.0M | $258.6M | $261.9M | $241.0M | $233.8M | $231.1M | $224.6M | $214.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.6M | $-30.1M | $-23.8M | $-284000 | $-35.1M | $-5.8M | $-17.2M | $-74.3M |